This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site
This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
-
TargetCancer Foundation, Cambridge, Massachusetts, United States, 02139
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
TargetCancer Foundation,
Razelle Kurzrock, M.D., PRINCIPAL_INVESTIGATOR, Medical College of Wisconsin
Vivek Subbiah, M.D., PRINCIPAL_INVESTIGATOR, SCRI Development Innovations, LLC
Shumei Kato, M.D., PRINCIPAL_INVESTIGATOR, University of California, San Diego
2025-12